Physician profile
Ines Simoes
NPI 1417615048
$834.70
in general payments reported to CMS, 2019-2025
16 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $282 · 2024: $284 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $140.83 | 2023-2025 | Lifevest |
| Genzyme Corporation | $125.00 | 2024 | |
| Glaxosmithkline, LLC. | $124.62 | 2023 | Arexvy |
| Merck Sharp & Dohme LLC | $124.58 | 2023-2025 | Verquvo |
| Exact Sciences Corporation | $59.24 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $43.82 | 2024 | |
| Novartis Pharmaceuticals Corporation | $34.12 | 2024-2025 | |
| Harmony Biosciences LLC | $33.92 | 2023-2025 | Wakix |
| Irhythm Technologies, INC. | $32.83 | 2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $22.28 | 2025 | Eliquis |
| United Therapeutics Corporation | $16.99 | 2023 | Tyvaso |
| Novo Nordisk INC | $16.93 | 2024 | Ozempic, Rybelsus |
| Azurity Pharmaceuticals, INC. | $15.63 | 2025 | Alvesco |
| Janssen Pharmaceuticals, INC | $14.97 | 2023 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $14.57 | 2024 | Arcalyst |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $14.37 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ines Simoes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.